SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications
Emerging Microbes & Infections·
- DOI
- 10.1080/22221751.2021.1976598
- PMID
- 34490832
- PMCID
- PMC8451603
- OpenAlex
- W3197858244
- Study type
- Journal article
- Publisher
- Informa UK Limited
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The abstract indicates that non-human primate models may support preclinical investigation of SARS-CoV-2 mechanisms and assessment of vaccines and drugs. It does not provide evidence of effects on human health outcomes, population-level transmission, or public health interventions.
Structured evidence summary
Research question
The review examines the benefits and caveats of available non-human primate models for SARS-CoV-2, including their use in studying infection mechanisms, immune responses, vaccines, drugs, and clinical translation.
Study design
This is a peer-reviewed journal review article that summarizes existing evidence on non-human primate models for SARS-CoV-2.
Population and setting
The article concerns non-human primate models used in SARS-CoV-2 research. The supplied abstract does not specify particular primate species, sample sizes, institutions, or geographic settings.
Main findings
The review reports that several studies found non-human primates could be infected with SARS-CoV-2 and develop clinical signs such as fever, cough, and breathing difficulty, along with lung and immune-related abnormalities. It describes applications of these models in investigating infection routes and host immune responses and in evaluating vaccines and drugs.
Public-health relevance
The abstract indicates that non-human primate models may support preclinical investigation of SARS-CoV-2 mechanisms and assessment of vaccines and drugs. It does not provide evidence of effects on human health outcomes, population-level transmission, or public health interventions.
Important limitations
The abstract refers to caveats and the need for model optimization and clinical translation but does not specify those limitations. This summary is limited to the supplied single-article abstract and metadata; the original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable in the supplied evidence under SARS-CoV-2/COVID-19 and the topics of diagnostics, treatment, and vaccination. It provides research-model context only and does not establish or confirm a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 12 auditable classifier relationships to diseases, places, topics, and study design.